Alliance legacy 试验中保乳治疗后的局部/区域复发率
该研究纳入 1997 至 2010 年 5 项 Alliance legacy 试验中接受保乳手术和标准系统治疗的 4404 例乳腺癌女性,评估局部/区域复发率。总体 5 年复发率为 4.6%(95%CI 4.0-5.4%),三阴性亚型最高(7.1%),ER+或PR+且Her2+为3.4%、Her2-为4.0%;多因素分析显示淋巴结受累增加和三阴性亚型与复发正相关(P<0.0001)。
要点
- 保乳术后总体5年局部/区域复发率为4.6%。
- 三阴性亚型5年复发率最高,达7.1%。
- 淋巴结受累增加和三阴性亚型与复发独立相关。
核心结论
- Alliance legacy 试验中保乳治疗后局部/区域复发率显著低于历史估计值。
研究设计与样本
- 回顾性队列分析,纳入5项Alliance legacy试验中1997-2010年诊断并接受保乳手术和标准系统治疗的4404例乳腺癌女性。
主要发现
- 总体5年局部/区域复发率为4.6%(95%CI=4.0-5.4%)。
- ER+或PR+肿瘤中,Her2+者5年复发率3.4%(95%CI 2.0-5.7%),Her2-者4.0%(95%CI 3.2-4.9%)。
- 三阴性亚型5年复发率最高,为7.1%(95%CI 5.4-9.3%)。
- 多因素分析中,淋巴结受累增加和三阴性亚型与复发正相关(P<0.0001)。
关键数值与推荐
- 5年局部/区域复发率总体4.6%(95%CI=4.0-5.4%)。
- ER+或PR+且Her2+者5年复发率3.4%(95%CI 2.0-5.7%)。
- ER+或PR+且Her2-者5年复发率4.0%(95%CI 3.2-4.9%)。
- 三阴性亚型5年复发率7.1%(95%CI 5.4-9.3%)。
临床怎么用
- 该数据可用于保乳术后患者讨论和手术决策,尤其需关注三阴性亚型和淋巴结阳性患者的复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to evaluate local/regional recurrence rates after breast-conserving surgery in a cohort of patients enrolled in legacy trials of the Alliance for Clinical Trials in Oncology and to evaluate variation in recurrence rates by receptor subtype. BACKGROUND: Multiple randomized controlled trials have demonstrated equivalent survival between breast conservation and mastectomy, albeit with higher local/regional recurrence rates after breast conservation. However, absolute rates of local/regional recurrence have been declining with multi-modality treatment. METHODS: Data from 5 Alliance for Clinical Trials in Oncology legacy trials that enrolled women diagnosed with breast cancer between 1997 and 2010 were included. Women who underwent breast-conserving surgery and standard systemic therapies (n=4,404) were included. Five-year rates of local/regional recurrence were estimated from Kaplan-Meier curves. Patients were censored at the time of distant recurrence (if recorded as the first recurrence), death, or last follow-up. Multivariable Cox proportional hazards models were used to identify factors associated with time to local/regional recurrence, including patient age, tumor size, lymph node status, and receptor subtype. RESULTS: Overall 5-year recurrence was 4.6% (95% CI=4.0-5.4%). Five-year recurrence rates were lowest in those with ER+ or PR+ tumors (Her2+ 3.4% [95% CI 2.0-5.7%], Her2- 4.0% [95% CI 3.2-4.9%]) and highest in the triple-negative subtype (7.1% [95% CI 5.4-9.3%]). On multivariable analysis, increasing nodal involvement and triple-negative subtype were positively associated with recurrence ( P <0.0001). CONCLUSIONS: Rates of local/regional recurrence after breast conservation in women with breast cancer enrolled in legacy trials of the Alliance for Clinical Trials in Oncology are significantly lower than historic estimates. This data can better inform patient discussions and surgical decision-making.
引用
- Schumacher JR, Wiener AA, Greenberg CC, et al. Local/Regional Recurrence Rates After Breast-Conserving Therapy in Patients Enrolled in Legacy Trials of the Alliance for Clinical Trials in Oncology (AFT-01). Ann Surg. 2022. PMID: 36521077. doi:10.1097/SLA.0000000000005776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。